Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer
Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer
Adagene宣佈取得進展，擴大其蒙面抗CTLA-4安全體 ADG126 與默克Keytruda（Pembrolizumab）聯合應用於轉移性微衛星穩定型結直腸癌患者的臨床合作開發計劃
Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -
預計將於2024年在醫學會議上獲得更多MSS CRC患者的中期數據，每三週（第三季度）與pembrolizumab聯合給藥，劑量爲10 mg/kg-
Initiated evaluation of 20 mg/kg loading doses of ADG126 in combination with pembrolizumab to explore enhanced efficacy given superior therapeutic index of ADG126 -
開始評估 ADG126 與 pembrolizumab 聯合使用的 20 mg/kg 負荷劑量，以探索在 ADG126 優異的治療指數下增強療效-
Received clearance from China's Center for Drug Evaluation (CDE) to evaluate ADG126 in combination with pembrolizumab -
已獲得中國藥物評估中心（CDE）批准，可以評估 ADG126 與 pembrolizumab 聯合使用-
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。